Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.
AstraZeneca and Fresenius Medical Care will exit the kidney disease treatment developer in a $725m acquisition that could potentially rise to $2.1bn.
The mobile optimisation technology provider, whose backers include Verizon Ventures, is set to be bought by Volaris Group.
Siemens and Scania-backed Sennder has merged with fellow on-demand logistics provider Everoad to seize a larger chunk of the European marketplace.
Genscript Biotech's multiple myeloma-focused spinoff, which counts Eli Lilly and Johnson & Johnson among its investors, has completed an initial public offering in the US.
Capital One and Salesforce-backed cloud database provider Snowflake has confidentially filed for an initial public offering that could value it at up to $20bn.
RWS Holdings had bought language translation software developer Iconic Translation Machines, founded on DCU's research into translating patents.
Johnson & Johnson and Varian Medical Systems are in line for exits after cancer therapy developer Fusion filed for a $100m initial public offering.
The cancer diagnostics technology developer, formed five years ago when Qiagen acquired part of Enzymatics, has filed to float on the Nasdaq Global Market.
McMaster University spinout Fusion Pharmaceuticals has filed for a $100m IPO in the US, putting shareholders such as Facit in line for exits.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
